Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 106

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 106
---
 and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company’s research facilities in California and Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track R&D expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. 

The following tables provide details of research and development expenses for the periods indicated: 

(in thousands)Three Months Ended March 31, 2025% ofExpenseCategory Three Months Ended March 31, 2024% ofExpenseCategory Increase (Decrease) $% Candidate costs$71,191 54 %$41,129 41 %$30,062 73 %R&D discovery costs14,806 11 %17,562 17 %(2,756)(16)%Salaries26,907 20 %24,921 25 %1,986 8 %Facilities related6,737 5 %5,923 6 %814 14 %Total research and development expense, excluding non-cash expense$119,641 90 %$89,535 89 %$30,106 34 %Stock compensation7,888 6 %7,487 7 %401 5 %Depreciation and amortization5,573 4 %4,100 4 %1,473 36 %Total research and development expense$133,102 100 %$101,122 100 %$31,980 32 %

26

(in thousands)Six Months Ended March 31, 2025% ofExpenseCategory Six Months Ended March 31, 2024% ofExpenseCategory Increase (Decrease)$%Candidate costs$148,087 55 %$94,085 43 %$54,002 57 %R&D discovery costs27,742 10 %39,102 18 %(11,360)(29)%Salaries54,052 20 %47,516 22 %6,536 14 %Facilities related14,487 5 %12,465